Literature DB >> 30862698

Clinical Pharmacology of Antibiotics.

Rachel F Eyler1,2, Kristina Shvets2.   

Abstract

Antimicrobial pharmacology and its effect on prescribing is quite complex. Selecting an antibiotic that will optimally treat an infection while minimizing adverse effects and the development of resistance is only the first step, as one must also consider the patient's individual pharmacokinetic alterations and the pharmacodynamic properties of the drug when prescribing it as well. Patients with CKD may have alterations in their protein binding, volumes of distribution, kidney clearance, and nonrenal clearance that necessitates antibiotic dose adjustments to prevent the development of toxicity. Knowledge of a drug's pharmacodynamics, defined as the relationship between drug exposure and antibacterial efficacy, provides some guidance regarding the optimal way to make dose adjustments. Different pharmacodynamic goals, such as maximizing the time that free (unbound) drug concentrations spend above the minimum inhibitory concentration (MIC) for time dependent drugs (e.g., β-lactams) or maximizing the free peak-to-MIC ratio for concentration-dependent antibiotics (e.g., aminoglycosides), require different adjustment strategies; for instance, decreasing the dose while maintaining normal dosing frequency or giving normal (or even larger) doses less frequently, respectively. Patients receiving hemodialysis have other important prescribing considerations as well. The nephrologist or patient may prefer to receive antibiotics that can be administered intravenously toward the end of a dialysis session. Additionally, newer dialysis technologies and filters can increase drug removal more than originally reported. This review will discuss the place in therapy, mechanism of action, pharmacokinetic, pharmacodynamic, and other pharmacologic considerations encountered when prescribing commonly used antibiotics in patients with chronic kidney disease or ESKD.
Copyright © 2019 by the American Society of Nephrology.

Entities:  

Keywords:  Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Kidney Failure, Chronic; Lactams; Metabolic Clearance Rate; Microbial Sensitivity Tests; Protein Binding; Renal Insufficiency, Chronic; antibiotics; chronic renal disease; end-stage renal disease; hemodialysis; pharmacodynamics; pharmacokinetics; pharmacology; renal dialysis

Mesh:

Substances:

Year:  2019        PMID: 30862698      PMCID: PMC6625637          DOI: 10.2215/CJN.08140718

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  49 in total

1.  Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers.

Authors:  K M Sowinski; B A Mueller; D W Grabe; H J Manley; R F Frye; G R Bailie; M A Marx
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

Review 2.  Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.

Authors:  Francesco Scaglione; Luca Paraboni
Journal:  Expert Rev Anti Infect Ther       Date:  2006-06       Impact factor: 5.091

3.  Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Authors:  Thomas P Lodise; Ben Lomaestro; George L Drusano
Journal:  Clin Infect Dis       Date:  2007-01-02       Impact factor: 9.079

4.  Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States.

Authors:  Blanche M Chavers; Craig A Solid; David T Gilbertson; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2007-01-24       Impact factor: 10.121

5.  Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Martin E Stryjewski; Lynda A Szczech; Daniel K Benjamin; Jula K Inrig; Zeina A Kanafani; John J Engemann; Vivian H Chu; Maria J Joyce; L Barth Reller; G Ralph Corey; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2006-12-08       Impact factor: 9.079

Review 6.  Trimethoprim-sulfamethoxazole revisited.

Authors:  Philip A Masters; Thomas A O'Bryan; John Zurlo; Debra Q Miller; Nirmal Joshi
Journal:  Arch Intern Med       Date:  2003-02-24

7.  Surveillance of hemodialysis-associated primary bloodstream infections: the experience of ten hospital-based centers.

Authors:  Margaret Dopirak; Connie Hill; Marylee Oleksiw; Diane Dumigan; Jean Arvai; Ellen English; Evelyn Carusillo; Susan Malo-Schlegel; Jeana Richo; Karen Traficanti; Bobbie Welch; Brian Cooper
Journal:  Infect Control Hosp Epidemiol       Date:  2002-12       Impact factor: 3.254

Review 8.  Pharmacodynamics and dosing of aminoglycosides.

Authors:  John Turnidge
Journal:  Infect Dis Clin North Am       Date:  2003-09       Impact factor: 5.982

Review 9.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Epidemiology of acute infections among patients with chronic kidney disease.

Authors:  Lorien S Dalrymple; Alan S Go
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 8.237

View more
  14 in total

1.  A validated LC-MS/MS method for the quantitation of cefazolin in human adipose tissue: Application of EMR-Lipid sorbent as an efficient sample clean-up before mass spectrometric analyses.

Authors:  Anna Siemiątkowska; Andrew Wassef; Ragui Sadek; Celine Park; Christine Yohn; Luigi Brunetti; Leonid Kagan
Journal:  J Pharm Biomed Anal       Date:  2022-02-28       Impact factor: 3.571

2.  A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.

Authors:  Firat Kaya; Jacqueline P Ernest; Katherine LoMauro; Martin Gengenbacher; Abdeldjalil Madani; Wassihun Wedajo Aragaw; Matthew D Zimmerman; Jansy P Sarathy; Nadine Alvarez; Isaac Daudelin; Han Wang; Faye Lanni; Danielle M Weiner; Laura E Via; Clifton E Barry; Kenneth N Olivier; Thomas Dick; Brendan K Podell; Radojka M Savic; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2022-01-31       Impact factor: 5.938

Review 3.  Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States.

Authors:  Marie N Celestin; Florin M Musteata
Journal:  J Pharm Sci       Date:  2021-06-02       Impact factor: 3.784

4.  Is it Worth Combining Solidago virgaurea Extract and Antibiotics against Uropathogenic Escherichia coli rods? An In Vitro Model Study.

Authors:  Dorota Wojnicz; Dorota Tichaczek-Goska; Michał Gleńsk; Andrzej B Hendrich
Journal:  Pharmaceutics       Date:  2021-04-17       Impact factor: 6.321

Review 5.  Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.

Authors:  Iwona Filipska; Agata Winiarska; Monika Knysak; Tomasz Stompór
Journal:  Toxins (Basel)       Date:  2021-04-10       Impact factor: 4.546

6.  Comparative genomics of Chinese and international isolates of Escherichia albertii: population structure and evolution of virulence and antimicrobial resistance.

Authors:  Lijuan Luo; Hong Wang; Michael J Payne; Chelsea Liang; Li Bai; Han Zheng; Zhengdong Zhang; Ling Zhang; Xiaomei Zhang; Guodong Yan; Nianli Zou; Xi Chen; Ziting Wan; Yanwen Xiong; Ruiting Lan; Qun Li
Journal:  Microb Genom       Date:  2021-12

7.  Antibacterial activity of endosymbiotic bacterial compound from Pheretima sp. earthworms inhibit the growth of Salmonella Typhi and Staphylococcus aureus: in vitro and in silico approach.

Authors:  Dirayah Rauf Husain; Riuh Wardhani
Journal:  Iran J Microbiol       Date:  2021-08

Review 8.  Antimicrobial Resistance and Inorganic Nanoparticles.

Authors:  Andrea-Sarahí Balderrama-González; Hilda-Amelia Piñón-Castillo; Claudia-Adriana Ramírez-Valdespino; Linda-Lucila Landeros-Martínez; Erasmo Orrantia-Borunda; Hilda-Esperanza Esparza-Ponce
Journal:  Int J Mol Sci       Date:  2021-11-29       Impact factor: 5.923

Review 9.  Pharmacokinetics in children with chronic kidney disease.

Authors:  Anne M Schijvens; Saskia N de Wildt; Michiel F Schreuder
Journal:  Pediatr Nephrol       Date:  2019-08-02       Impact factor: 3.714

Review 10.  Antibiotics and the Nervous System-Which Face of Antibiotic Therapy Is Real, Dr. Jekyll (Neurotoxicity) or Mr. Hyde (Neuroprotection)?

Authors:  Magdalena Hurkacz; Lukasz Dobrek; Anna Wiela-Hojeńska
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.